These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12120879)

  • 21. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
    Unal S; Garcia-Rodriguez JA
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
    Jones RN; Mendes C; Turner PJ; Masterton R
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYSTIC program: summary of European data from 1997 to 2000.
    Goossens H;
    Diagn Microbiol Infect Dis; 2001 Dec; 41(4):183-9. PubMed ID: 11777657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
    Metan G; Zarakolu P; Hasçelik G; Akova M
    Mikrobiyol Bul; 2006; 40(1-2):23-8. PubMed ID: 16775953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000.
    Pfaller MA; Jones RN;
    Int J Antimicrob Agents; 2002 May; 19(5):383-8. PubMed ID: 12007846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003).
    Turner PJ
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):291-3. PubMed ID: 15582303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).
    Turner PJ
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):281-9. PubMed ID: 15808320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN; Kirby JT; Rhomberg PR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):443-8. PubMed ID: 24492025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance surveillance in Italy: four-year results from the MYSTIC program.
    Fontana R; Lo Cascio G; Giacobone E; Romero E; Cipriani P; Sessa R; Franchino L
    J Chemother; 2002 Aug; 14(4):323-31. PubMed ID: 12420847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility surveillance among gram-negative bacilli at a cancer center.
    Jacobson K; Rolston K; Elting L; LeBlanc B; Whimbey E; Ho DH
    Chemotherapy; 1999; 45(5):325-34. PubMed ID: 10473920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme.
    Garcia-Rodriguez JA; Jones RN;
    J Chemother; 2002 Feb; 14(1):25-32. PubMed ID: 11892895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V; Ulusoy S; Zarakolu P; Mete B;
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
    Pfaller MA; Jones RN
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():25-37. PubMed ID: 11065146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.
    Masterton RG; Kuti JL; Turner PJ; Nicolau DP
    J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.